Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Jul 8;24(1):11-3.
doi: 10.1016/j.ccr.2013.06.007.

GEMMs shine a light on resistance to androgen deprivation therapy for prostate cancer

Theodoros Karantanos  1 , Timothy C Thompson
Affiliations

GEMMs shine a light on resistance to androgen deprivation therapy for prostate cancer

Theodoros Karantanos et al. Cancer Cell. .

Erratum in

  • Cancer Cell. 2013 Aug 12;24(2):272

Abstract

Androgen deprivation therapy (ADT) for advanced prostate cancer inexorably leads to resistance, and clinically useful biomarkers are lacking. The value of genetically engineered mice for coclinical studies is clearly demonstrated in a recent publication that reveals XAF1, XIAP, and SRD5A1 as novel predictive biomarkers and therapeutic targets for ADT resistance.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest.

Figures

Figure 1
Figure 1. The genetic profile of prostate cancers predicts response to ADT and guides therapeutic decisions
Prostate cancers with genetic alterations resulting from PTEN deletion will present initial sensitivity to ADT translated to an early tumor regression, but the acquisition of oncogenic events and alterations will lead to an acquired resistance to ADT and cancer relapse. These tumors demonstrate XAF1 downregulation and XIAP and SRD5A1 upregulation. Prostate cancers with TP53 and ZBTB7A deletions will present initial resistance to ADT while the addition of embelin and dutasteride will increase their sensitivity to ADT and eventually lead to tumor regression. The potential sensitivity of tumors with initial resistance related to this XAF1, XIAP, and SRD5A1 genetic profile to embelin and dutasteride may provide a second-line therapy for cancers with poor response to ADT.
See this image and copyright information in PMC

References

    1. Huggins C, Hodges CV. Cancer Res. 1941;1:293–297.
    1. Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, Rosenfeld MG, Sawyers CL. Molecular determinants of resistance to antiandrogen therapy. Nat Med. 2004;10:33–39. - PubMed
    1. Cai C, He HH, Chen S, Coleman I, Wang H, Fang Z, Chen S, Nelson PS, Liu XS, Brown M, Balk SP. Androgen receptor gene expression in prostate cancer is directly suppressed by the androgen receptor through recruitment of lysine-specific demethylase 1. Cancer Cell. 2011;18:457–451. - PMC - PubMed
    1. Lunardi A, Ala U, Epping MT, Salmena L, Clohessy JG, Webster KA, Wang G, Mazzucchelli R, Bianconi M, et al. A co-clinical approach identifies mechanisms and potential therapies for androgen deprivation resistance in prostate cancer. Nat Genet. 2013 Epub ahead of print. - PMC - PubMed
    1. Taylor BS, Schulz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, Arora VK, Kaushik P, Cerami E, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell. 2010;18:11–22. - PMC - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources